Development and Validation of a Cuproptosis‐Based Risk Score Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Transcriptomic Analysis
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/6097777 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Breast Journal, online erschienen am 29.05.2026. Verfasst von Lihai Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, 154003, Heilongjiang, China, jmsuf1.cj68.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Cuproptosis, Neoadjuvant Therapy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Provincial Science and Technology Department.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study developed a cuproptosis‐related transcriptomic risk score model to predict neoadjuvant chemotherapy (NAC) response in breast cancer (BC) patients and explored its association with the tumor immune microenvironment.
Methods
Analysis of transcriptomic and clinical data from TCGA and GEO revealed differentially expressed cuproptosis‐related genes. LASSO‐based Cox regression was used to build the risk score. Model performance was evaluated using Kaplan–Meier survival, ROC curves, and GSEA/GSVA in the training cohort and further validated in an independent external cohort. Drug sensitivity was predicted using the oncoPredict tool, and RT‐qPCR was used to validate key gene expression.
Results
A 10‐gene prognostic model was developed based on the identification of 71 cuproptosis‐related genes. The risk score correlated with survival outcomes, PAM50 subtypes, tumor stage, and pathologic response. It showed good predictive performance in both training (AUC = 0.719) and testing (AUC = 0.689) cohorts. Key genes (CIRBP, INPP4B, IL6ST, and CCL20) were validated and linked to NAC response.
Conclusion
The cuproptosis‐based risk score model effectively predicts NAC response and may guide personalized treatment in BC. It also reveals the relevance of cuproptosis‐related genes in immune modulation and chemotherapy sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, 154003, Heilongjiang, China, jmsuf1.cj68.com.
- Department of Pediatric, The First Affiliated Hospital of Jiamusi University, Jiamusi, 154003, Heilongjiang, China, jmsuf1.cj68.com.
- Graduate School, Jiamusi University, Jiamusi, 154007, Heilongjiang, China, jmsu.edu.cn.
ORCID-Profile: Lihai Zhang
Förderung
- Heilongjiang Provincial Science and Technology Department
Zitieren
APA
Zhang, L., Wang, J., Tan, B., Wang, X., & Luan, Z. (2026). Development and Validation of a Cuproptosis‐Based Risk Score Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Transcriptomic Analysis. The Breast Journal, 2026(1). https://doi.org/10.1155/tbj/6097777
Vancouver
Zhang L, Wang J, Tan B, Wang X, Luan Z. Development and Validation of a Cuproptosis‐Based Risk Score Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Transcriptomic Analysis. The Breast Journal. 2026;2026(1). doi:10.1155/tbj/6097777
BibTeX
@article{Zhang2026,
author = {Zhang, Lihai and Wang, Jiao and Tan, Baihong and Wang, Xingquan and Luan, Zhenglong},
title = {Development and Validation of a Cuproptosis‐Based Risk Score Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Transcriptomic Analysis},
journal = {The Breast Journal},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/tbj/6097777}
}
EUVIMED